China Manufacturer Supply Weight Loss Peptide LY3437943 CAS 2381089-83-2 Retatrutide

What is retatrutide?

Retatrutide is a new weight loss drug by Eli Lilly, the makers of Mounjaro, a diabetes drug that can lead to significant weight loss. Retatrutide is injected subcutaneously (under the skin) once a week, just like Ozempic, Mounjaro, and other weight loss medications like Wegovy. Retatrutide is currently being tested for treating obesity, type 2 diabetes, or both. Thus far, the results are promising. ​

How does retatrutide compare to other weight-loss drugs? ​

Weight loss drugs like Ozempic and Wegovy belong to a drug class known as glucagon-like peptide-1 (GLP-1) receptor agonists. They work by mimicking a gut hormone called GLP-1, which helps to encourage insulin release while also sending fullness signals to your brain to tell you that you’re full. The drugs also delay gastric emptying, slowing the process in which food moves from your stomach into the small intestine. Together, these effects help to lower blood sugar — good for people with type 2 diabetes — and lead to weight loss — good for people looking to lose weight, with or without type 2 diabetes. Mounjaro (tirzepatide), another medication by Eli Lilly, is unique among the GLP-1 drug family because in addition to activating the GLP-1 receptor, it also targets glucose-dependent insulinotropic polypeptide (GIP), another hormone involved in insulin release. By working together, Mounjaro has a synergistic effect that leads to even more weight loss and improved blood sugar control. Indeed, people taking the highest dose of Mounjaro lose nearly 21% of their body weight, on average, within a year and a half. By comparison, people taking the highest dose of Wegovy (semaglutide) lose around 15% of their body weight in the same time frame. “GLP-1 receptor agonists and GIP receptor agonists work on the body in very similar ways,” shared Dr. Sergio Alvarez, MD, a Miami, FL-based board-certified plastic surgeon and CEO of Mia Aesthetics. Retatrutide is different in that in addition to GLP-1 and GIP receptors, it also works on the glucagon receptor. “Glucagon tells the liver to release sugar stored in the body. Since sugar is largely stored as fat, the body in turn breaks this fat down, resulting in weight loss”, Dr. Alvarez explains. This three-pronged activation may contribute to the superior weight loss effects of retatrutide in comparison to other GLP-1 drugs, as clinical trials have shown so far. As we mentioned earlier, in one of the studies, people taking the highest dose of retatrutide lost about 24% of their body weight in 48 weeks. So, they lost more weight than someone taking Mounjaro and did so in about two-thirds the time.